(Press-News.org) Alexandria, VA, USA – Members of the International Association for Dental, Oral, and Craniofacial Research (IADR) have elected George Belibasakis, Karolinska Institutet, Stockholm, Sweden to serve as Vice-president. His term will commence at the conclusion of the 104th General Session of the IADR, which will be held in conjunction with the 55th Annual Meeting of the AADOCR and the 50th Annual Meeting of the Canadian Association for Dental Research, from March 25-28, 2026 in San Diego, CA, USA.
Belibasakis is currently Professor of Clinical Oral Infection Biology, Head of the Division of Oral Health and Periodontology, and Head of Research at the Department of Dental Medicine, Karolinska Institutet in Stockholm, Sweden. He received his D.D.S. at Aristotle University of Thessaloniki, Greece and his Ph.D. in Oral Microbiology at Umeå University, Sweden. He completed his Postdoctoral Fellowship at King´s College London, UK and received his M.Sc. in Periodontology at Queen Mary University of London, UK.
Belibasakis’s research is largely focused on deciphering the biological mechanisms underlying common oral diseases. He strongly believes that understanding in depth the biology of oral disease is the preamble for clinically innovative diagnostic and therapeutic modalities, in the context of precision healthcare. Hence, his aspirations are to discover/validate clinical biomarkers and novel antimicrobials, develop molecular-based chair-side diagnostics, and explore the associations between oral and systemic health.
Since joining the IADR in the late 1990s, Belibasakis has been a member of the British, Scandinavian, and Continental European Divisions. He has served in various committees and in different roles, including the IADR Periodontal Research, Microbiology and Immunology, and the Implantology Research Groups. He has served on the IADR Fellowships Committee, the IADR/AADOCR Publications Committee, the IADR Annual Session Committee, and on the Journal of Dental Research Editorial Board.
About IADR
The International Association for Dental, Oral, and Craniofacial Research is a nonprofit organization with a mission to drive dental, oral, and craniofacial research for health and well-being worldwide. IADR represents the individual scientists, clinician-scientists, dental professionals, and students based in academic, government, non-profit, and private-sector institutions who share our mission. Learn more at www.iadr.org.
END
IADR elects George Belibasakis as vice-president
2025-12-08
ELSE PRESS RELEASES FROM THIS DATE:
Expanding the search for quantum-ready 2D materials
2025-12-08
Quantum technologies from ultrasensitive sensors to next-generation information processors depend on the ability of quantum bits, or qubits, to maintain their delicate quantum states for a sufficiently long time to be useful.
One of the most important measures of this stability is the spin coherence time. Unfortunately, qubits may lose coherence because their environment is “noisy,” for example, due to the presence of nuclear isotopes or other interference that disturbs the qubit.
Two-dimensional (2D) materials—or atomically thin sheets—can offer quiet environments for qubits, as their reduced thickness naturally lowers the number of isotopes that interact ...
White paper on leadership opportunities for AI to increase employee value released by University of Phoenix College of Doctoral Studies
2025-12-08
University of Phoenix College of Doctoral Studies announces a new white paper, “Leadership Opportunities for Increasing Employee Value through Artificial Intelligence,” authored by Andrew C. Lawlor, PhD, and Pamayla E. Darbyshire, DHA, MSN/CNS, both Fellows at the Center for Educational and Instructional Technology Research (CEITR). The paper examines how leaders can use AI, especially generative AI, to address skills gaps, restore worker autonomy, and shift employees from repetitive tasks to higher-value activities.
The authors draw upon the University’s Career Optimism Index® study and other current research, ...
ASH 2025: New combination approach aims to make CAR T more durable in lymphoma
2025-12-08
MIAMI, FLORIDA (EMBARGOED UNTIL DEC. 8, 2025, AT 4:30 P.M. EST) – A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may sharply boost one-year progression-free survival for people with aggressive lymphoma.
In just a few years, treatment options for aggressive lymphoma have rapidly advanced. However, many patients show a consistent pattern: powerful new therapies act quickly but often fail to keep the lymphoma at bay permanently, says Jay Spiegel, M.D., a transplant and cellular therapy physician at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.
Spiegel ...
‘Ready-made’ T-cell gene therapy tackles ‘incurable’ T-cell leukemia
2025-12-08
A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street Hospital (GOSH), has shown promising results in helping children and adults fight a rare and aggressive form of blood cancer called T-cell acute lymphoblastic leukaemia (T-ALL).
The world-first gene therapy (BE-CAR7) uses base-edited immune cells to treat previously untreatable T-cell leukaemia and help patients achieve remission, offering new hope for families facing this aggressive cancer. Base-editing is an advanced version of CRISPR technology, that can precisely change single ...
How brain activity changes throughout the day
2025-12-08
An international team led by the University of Michigan has introduced new methods that reveal which regions of the brain were active throughout the day with single-cell resolution.
Using mouse models, the researchers developed an experimental protocol and a computational analysis to follow which neurons and networks within the brain were active at different times. Published in the journal PLOS Biology, the study provides new insights into brain signaling during sleep and wakefulness, which hints at the bigger questions and goals that motivated the work.
"We undertook this difficult study to understand fatigue," ...
Australian scientists reveal new genetic risk for severe macular degeneration
2025-12-08
Australian researchers have for the first time pinpointed specific genetic changes that increase the risk of severe, sight-threatening forms of age-related macular degeneration (AMD).
A new study, published today in Nature Communications, reveals the specific genetic factors linked to the presence of reticular pseudodrusen - deposits which drive vision loss and are found on the retina of up to 60 per cent of people with advanced AMD.
The research, led by the Centre for Eye Research Australia, WEHI and the University of Melbourne, offers a promising new target for treatments aimed at the most severe ...
GLP-1 receptor agonists likely have little or no effect on obesity-related cancer risk
2025-12-08
Embargoed for release until 5:00 p.m. ET on Monday 8 December 2025
Follow @Annalsofim on X, Facebook, Instagram, Bluesky, and Linkedin
Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of information. This information is under strict embargo and by taking it into possession, media representatives are committing to the terms of the embargo not only on their own behalf, but also on behalf of the organization ...
Precision immunotherapy to improve sepsis outcomes
2025-12-08
About The Study: Among patients with sepsis, precision immunotherapy targeting macrophage activation–like syndrome and sepsis-induced immunoparalysis improved organ dysfunction by day 9 compared with placebo.
Corresponding Author: To contact the corresponding author, Evangelos J. Giamarellos-Bourboulis, MD, PhD, email egiamarel@med.uoa.gr.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2025.24175)
Editor’s Note: Please see the article for additional information, including other ...
Insilico Medicine unveils winter edition of Pharma.AI, accelerating the path to pharmaceutical superintelligence
2025-12-08
The topics of human-level artificial general intelligence (AGI) and artificial superintelligence (ASI) have captivated researchers for decades. Interest has surged with the rapid progress and deployment of large language models (LLMs), which now handle tasks such as coding, scientific explanation, creative writing, and multimodal reasoning. “Solve AI and it will solve everything” remains a popular, if contested, credo—driving large-scale investment, shaping public narratives, and motivating optimism about transformative advances.
Applying this vision to the healthcare and pharmaceutical industries, ...
Study finds most people trust doctors more than AI but see its potential for cancer diagnosis
2025-12-08
FOR IMMEDIATE RELEASE
EMBARGOED UNTIL DECEMBER 8, 2025
Study Finds Most People Trust Doctors More than AI But See Its Potential for Cancer Diagnosis
Nationally representative surveys measure public attitudes toward AI in healthcare
Washington, D.C., December 8, 2025– New research on public attitudes toward AI indicates that most people are reluctant to let ChatGPT and other AI tools diagnose their health condition, but see promise in technologies that use AI to help diagnose cancer. These and other results of two nationally representative surveys will be presented at the ...